$METROPOLIS (Diagnostics): B2C mix & operating leverage

Diagnostics is shifting from B2B volume to B2C brand, convenience and packages. Metropolis Healthcare has leaned into that pivot: FY25 B2C revenue grew ~17% YoY with premium “TruHealth” packages pushing realisations; EBITDA margins tracked mid-20s in FY25 despite integration costs, highlighting operating leverage as scale improves. The network strategy is deliberate—expand into Tier-2/3 with labs + 500 new centres (this FY) and push toward presence in ~1,000 towns in ~12–18 months. Industry structure is a tailwind: organised diagnostics is expected to compound at low-to-mid-teens as preventive health, chronic disease management and digital journeys deepen penetration. Nuance: B2C brings brand and margin, but also marketing intensity and aggregator pricing pressure; acquisitions (e.g., Core Diagnostics) help test-menu and speciality depth, but dilute margins near-term during integration. Watch test-mix (high-yield packages vs routine), home-collection density, and B2C share rising toward 60%+—that’s the profit flywheel. Also track seasonal swings (vector/viral cycles) and any regulatory changes on pricing. If execution holds—strong NPS, tight cost control, and disciplined M&A— $METROPOLIS can keep expanding margins while compounding topline in double digits, a rare mix in healthcare services.